Cookie Consent
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
SCOPE is an international and independent full-service contract research organization (CRO) known as a reliable and trusted partner for many pharma, biotech and medical device companies. We have a great expertise in delivering clinical trials for development programs in the field of infectious diseases. One of our major USPs (unique selling point) is our close relationship with sites and a vast network of experts and key opinion leaders in the field.
Emphasized by the COVID-19-pandemic, infectious diseases with the potential to severely impact public health and economies have raised high interest for the development of new vaccines and cures. The need for clinical trial expert leadership is paramount to achieve fast bench-to-market timelines, especially when developing new drugs for unmet needs.
SCOPE provides this kind of expert leadership across the major market – EUROPE – that will make the difference for your clinical development programs and for the time to market, making new therapies available even faster for the benefit of public health and economies.
We work with in a network of fully operational local offices across Europe. Other areas are covered with well-established partners, all tailored to the need of your project and for the best performance of your trial.
Whether it’s a clinical developmental trial in phase I-III, post-authorization study in phase IV, study rescue, SCOPE has the expertise, know-how and resources to guide you through all phases of development while meeting your objectives and expectations.
SCOPE’s team has managed clinical trials (Phase I-IV) for:
SCOPE’s full-service portfolio offers you the whole set of fully integrated services while working with one dedicated Project Manager and the PM’s team. You will have the best team for the successful and efficient preparation and setup, submissions, conduct and close-out of your study.
COVID-19 has shown how dynamic the pandemic situation and the challenges for clinical research can be. With experience, flexibility and a pragmatic approach, SCOPE has established new, unique and regulatory sound processes to maintain recruitment in all clinical trials.
e.g. Arthritis-related Pain, Bladder Pain Syndrome, Cancer Pain, Chronic Pain, Headache / Migraine, Lower Back Pain, Neuropathic Pain (diabetic, postherpetic), Postoperative Pain Management, Rheumatic Pain, Acute Postoperative / Procedural Pain
e.g. ART (IVF, ICSI), Contraception, Endometriosis, Fibromyalgia Syndrome (FMS), Obstetrics, Oncology, Pain Management, PCOS, Polymyalgia Rheumatica, Postmenopausal Complaints, Preterm labor, Rheumatoid Arthritis, Vulvar and Vaginal Atrophy, Vulvovaginal Candidiasis
e.g. Asthma (mild, moderate, severe, paediatric), Asthma / COPD Overlap Syndrome (ACOS), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired Pneumonia (CAP), COVID-19, Respiratory Virus Infection (including paediatric)
e.g. Alzheimer’s Disease, Bipolar Disorder, Depression, Epilepsy (including paediatric), Mania, Multiple Sclerosis, Narcolepsy, Parkinson’s Disease, Sensorineural Disorder
e.g. Community-acquired pneumonia (CAP), COVID-19, GI and Intra-Abdominal Infections, Immune-Modulator to prevent SARS-CoV Complication, Respiratory Virus Infections (including paediatric)
e.g. Cell and Gene Therapies, Early-Phase Clinical Development of ATMPs, Immunotherapy, Personalized Therapies, Regenerative Medicine
e.g. acute myocardial infarction, hypertension, peripheral arterial disease (PAD), pulmonary arterial hypertension (PAH) and stable angina pectoris
e.g. allergy (allergic conjunctivitis/ rhinoconjunctivitis), dermatomyositis, primary immunodeficiency diseases (PIDs) and vaccination (hepatitis B, influenza, rabies, tuberculosis)
e.g. acute porphyria and type 1 diabetes
e.g. hematological malignancy, liver cancer, metastatic breast cancer, metastatic lung tumor, non-Hodgkin lymphoma, prostatic cancer, renal cancer, schwannoma resection, solid tumors, unresectable cholangiocarcinoma and urinary bladder cancer
e.g. caries prophylaxis
e.g. alopecia areata, hypertrophic scars and psoriasis
e.g. acute porphyria, hormone replacement therapies in women, type 1 diabetes and vitamin D deficiency
e.g. acute porphyria, cholecystectomy, colitis ulcerosa, constipation, fat absorption in HIV-infected patients, inflammatory bowel disease (IBD), intra-abdominal infections, irritable bowel syndrome (IBS), liver disease, cholecystectomy and unresectable cholangiocarcinoma
e.g. hepatitis B vaccination, hepatic impairment, liver cancer and liver disease
e.g. Alzheimer’s, asthma, colitis ulcerosa, osteoarthritis, Parkinson’s Disease, polymyalgia rheumatica (PMR), psoriasis and rheumatoid arthritis
e.g. allergic conjunctivitis, keratoconjunctivitis and retinopathy
e.g. acute porphyria, juvenile dermatomyositis, polymyalgia rheumatica (PMR), pulmonary arterial hypertension (PAH) and sudden sensorineural hearing loss (SSNHL)
e.g. cartilage defects, open Gustilo-Anderson grade IIIa/IIIb tibia shaft fractures and osteoarthritis
e.g. acute peripheral vertigo, acute sensorineural hearing loss (ASNHL), rhinoconjunctivitis and sudden sensorineural hearing loss (SSNHL)
e.g. bladder pain syndrome, prostatic cancer, renal cancer, renal dysfunction / failure
and urinary bladder cancer
e.g. hepatitis B, influenza, rabies and tuberculosis
